1110 — Kingworld Medicines Share Price
0.000.00%
Last trade - 00:00- HK$348.60m
- HK$581.29m
- CNY1.06bn
- 43
- 97
- 32
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.48 | ||
| Price to Tang. Book | 0.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.29 | ||
| EV to EBITDA | 4.85 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.96% | ||
| Return on Equity | 6.6% | ||
| Operating Margin | 8.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 745.38 | 847.39 | 957.7 | 1,078.66 | 1,061.08 | n/a | n/a | 1.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -74.29 | +184.92 | -27.96 | +73.94 | +11.67 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kingworld Medicines Group Ltd is an investment holding company primarily engaged in the distribution sale of branded imported pharmaceutical and healthcare products. The Company operates its business through two segments. The Distribution Sales of Pharmaceutical and Health Care Products segment engages in distribution and sales of branded imported pharmaceutical and healthcare products. The Company’s distribution products include Nin Jiom Pei Pa Koa, Taiko Seirogan, Culturelle Probiotics and other products. The Manufacturing and Sales of Electrotherapeutic and Physiotherapeutic Devices and General Medical Examination Devices segment engages in the manufacturing and sales of electrotherapeutic and physiotherapeutic devices and general medical examination devices. The Company’s medical devices and equipment products include infrared thermometers, handheld electrophysical therapeutic products and other products. The Company conducts its business in the domestic and overseas markets.
Directors
- Li Sheng Zhao CHM (56)
- Hon Wan Chan CTR (54)
- Lok San Chan EDR (51)
- Xuhua Zhou EDR (48)
- Yun Ceng OTH (44)
- Danna Fang OTH (49)
- Ruozhong Huang OTH (52)
- Caiyun Liang OTH (46)
- Yibing Liu OTH (56)
- Yongli Tian OTH (52)
- Dan Zhang OTH (50)
- Jidong Duan NID (50)
- Cheuk Lam Wong NID (48)
- Jianbin Zhang NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 10th, 2008
- Public Since
- November 25th, 2010
- No. of Employees
- 739
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 622,500,000
- Address
- 10F, Block A, Tian An International Bldg, SHENZHEN, 518016
- Web
- https://www.kingworld.com.cn/
- Phone
- +86 75582292888
- Auditors
- Crowe Horwath (HK) CPA Limited
Upcoming Events for 1110
Dividend For 1110.HK - 0.0317 HKD
Similar to 1110
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
What is the Kingworld Medicines share price?
As of Today at 21:35 UTC, shares in Kingworld Medicines are trading at HK$0.53. This share price information is delayed by 15 minutes.
How has the Kingworld Medicines share price performed this year?
Shares in Kingworld Medicines last closed at HK$0.53 and the price had moved by over the past 365 days. In terms of relative price strength the Kingworld Medicines share price has outperformed the FTSE Developed Asia Pacific Index by +1.14% over the past year.
What are the analyst and broker recommendations for Kingworld Medicines?
There is no consensus recommendation for this security.
Find out moreWhat is the Kingworld Medicines dividend yield?
The Kingworld Medicines dividend yield is 5.98% based on the trailing twelve month period.
Does Kingworld Medicines pay a dividend?
Last year, Kingworld Medicines paid a total dividend of CNY0.03, and it currently has a trailing dividend yield of 5.98%.Looking ahead, shares in Kingworld Medicines are due to go ex-dividend on 2025-06-05 and the next dividend pay date is 2025-06-30.
When does Kingworld Medicines next pay dividends?
Kingworld Medicines are due to go ex-dividend on 2025-06-05 and the next dividend pay date is 2025-06-30. The historic dividend yield on Kingworld Medicines shares is currently 5.98%.
How do I buy Kingworld Medicines shares?
To buy shares in Kingworld Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kingworld Medicines?
As of the previous close price of HK$0.53, shares in Kingworld Medicines had a market capitalisation of HK$348.60m.
Where are Kingworld Medicines shares listed?
Here are the trading details for Kingworld Medicines:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1110
What kind of share is Kingworld Medicines?
Based on an overall assessment of its quality, value and momentum Kingworld Medicines is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kingworld Medicines share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Kingworld Medicines share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kingworld Medicines. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +10.12%.
As of the last closing price of HK$0.53, shares in Kingworld Medicines were trading +10.9% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kingworld Medicines PE Ratio?
The Kingworld Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$0.53.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kingworld Medicines?
Kingworld Medicines' management team is headed by:
- Li Sheng Zhao - CHM
- Hon Wan Chan - CTR
- Lok San Chan - EDR
- Xuhua Zhou - EDR
- Yun Ceng - OTH
- Danna Fang - OTH
- Ruozhong Huang - OTH
- Caiyun Liang - OTH
- Yibing Liu - OTH
- Yongli Tian - OTH
- Dan Zhang - OTH
- Jidong Duan - NID
- Cheuk Lam Wong - NID
- Jianbin Zhang - NID